Intrinsic value of Agenus Inc. - AGEN

Previous Close

$2.82

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$2.82

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of AGEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  69
  106
  159
  231
  325
  447
  601
  788
  1,015
  1,282
  1,591
  1,946
  2,345
  2,790
  3,281
  3,816
  4,396
  5,019
  5,684
  6,391
  7,138
  7,924
  8,750
  9,614
  10,516
  11,457
  12,437
  13,457
  14,517
  15,619
Variable operating expenses, $m
  77
  117
  174
  252
  354
  486
  651
  854
  1,098
  1,386
  1,718
  2,100
  2,532
  3,012
  3,542
  4,120
  4,746
  5,418
  6,137
  6,899
  7,706
  8,555
  9,446
  10,378
  11,353
  12,369
  13,427
  14,527
  15,672
  16,861
Fixed operating expenses, $m
  106
  109
  111
  113
  116
  119
  121
  124
  127
  129
  132
  135
  138
  141
  144
  147
  151
  154
  157
  161
  164
  168
  172
  175
  179
  183
  187
  191
  195
  200
Total operating expenses, $m
  183
  226
  285
  365
  470
  605
  772
  978
  1,225
  1,515
  1,850
  2,235
  2,670
  3,153
  3,686
  4,267
  4,897
  5,572
  6,294
  7,060
  7,870
  8,723
  9,618
  10,553
  11,532
  12,552
  13,614
  14,718
  15,867
  17,061
Operating income, $m
  -114
  -120
  -126
  -134
  -144
  -157
  -171
  -189
  -210
  -234
  -259
  -290
  -325
  -363
  -405
  -451
  -500
  -553
  -609
  -669
  -732
  -798
  -867
  -940
  -1,016
  -1,094
  -1,176
  -1,262
  -1,350
  -1,442
EBITDA, $m
  -105
  -107
  -108
  -109
  -110
  -110
  -110
  -109
  -108
  -106
  -103
  -100
  -95
  -90
  -84
  -78
  -70
  -62
  -54
  -44
  -34
  -23
  -12
  0
  12
  26
  39
  54
  69
  85
Interest expense (income), $m
  1
  21
  17
  29
  45
  67
  96
  133
  180
  237
  306
  388
  482
  591
  713
  849
  999
  1,162
  1,339
  1,530
  1,733
  1,949
  2,177
  2,418
  2,670
  2,934
  3,210
  3,497
  3,797
  4,108
  4,432
Earnings before tax, $m
  -135
  -137
  -155
  -179
  -211
  -252
  -304
  -369
  -447
  -540
  -646
  -772
  -915
  -1,076
  -1,254
  -1,449
  -1,662
  -1,892
  -2,139
  -2,402
  -2,681
  -2,975
  -3,285
  -3,610
  -3,949
  -4,304
  -4,673
  -5,058
  -5,458
  -5,874
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -135
  -137
  -155
  -179
  -211
  -252
  -304
  -369
  -447
  -540
  -646
  -772
  -915
  -1,076
  -1,254
  -1,449
  -1,662
  -1,892
  -2,139
  -2,402
  -2,681
  -2,975
  -3,285
  -3,610
  -3,949
  -4,304
  -4,673
  -5,058
  -5,458
  -5,874

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  182
  282
  422
  612
  863
  1,187
  1,593
  2,092
  2,691
  3,399
  4,221
  5,161
  6,220
  7,401
  8,702
  10,123
  11,661
  13,313
  15,078
  16,952
  18,933
  21,020
  23,209
  25,501
  27,895
  30,391
  32,990
  35,695
  38,507
  41,430
Adjusted assets (=assets-cash), $m
  182
  282
  422
  612
  863
  1,187
  1,593
  2,092
  2,691
  3,399
  4,221
  5,161
  6,220
  7,401
  8,702
  10,123
  11,661
  13,313
  15,078
  16,952
  18,933
  21,020
  23,209
  25,501
  27,895
  30,391
  32,990
  35,695
  38,507
  41,430
Revenue / Adjusted assets
  0.379
  0.376
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
Average production assets, $m
  72
  111
  166
  241
  340
  468
  628
  825
  1,061
  1,340
  1,665
  2,035
  2,453
  2,919
  3,432
  3,992
  4,598
  5,250
  5,946
  6,685
  7,466
  8,289
  9,152
  10,056
  11,000
  11,984
  13,009
  14,076
  15,185
  16,338
Working capital, $m
  -36
  -55
  -83
  -120
  -170
  -234
  -313
  -412
  -530
  -669
  -831
  -1,016
  -1,224
  -1,456
  -1,713
  -1,992
  -2,295
  -2,620
  -2,967
  -3,336
  -3,726
  -4,137
  -4,567
  -5,018
  -5,489
  -5,981
  -6,492
  -7,025
  -7,578
  -8,153
Total debt, $m
  134
  223
  349
  520
  746
  1,037
  1,403
  1,852
  2,392
  3,029
  3,768
  4,614
  5,568
  6,630
  7,802
  9,080
  10,464
  11,952
  13,540
  15,226
  17,010
  18,887
  20,858
  22,920
  25,075
  27,321
  29,661
  32,095
  34,626
  37,256
Total liabilities, $m
  164
  254
  379
  551
  777
  1,068
  1,434
  1,882
  2,422
  3,059
  3,799
  4,645
  5,598
  6,661
  7,832
  9,111
  10,495
  11,982
  13,570
  15,257
  17,040
  18,918
  20,888
  22,951
  25,105
  27,352
  29,691
  32,125
  34,656
  37,287
Total equity, $m
  18
  28
  42
  61
  86
  119
  159
  209
  269
  340
  422
  516
  622
  740
  870
  1,012
  1,166
  1,331
  1,508
  1,695
  1,893
  2,102
  2,321
  2,550
  2,789
  3,039
  3,299
  3,569
  3,851
  4,143
Total liabilities and equity, $m
  182
  282
  421
  612
  863
  1,187
  1,593
  2,091
  2,691
  3,399
  4,221
  5,161
  6,220
  7,401
  8,702
  10,123
  11,661
  13,313
  15,078
  16,952
  18,933
  21,020
  23,209
  25,501
  27,894
  30,391
  32,990
  35,694
  38,507
  41,430
Debt-to-equity ratio
  7.330
  7.920
  8.280
  8.500
  8.650
  8.740
  8.810
  8.850
  8.890
  8.910
  8.930
  8.940
  8.950
  8.960
  8.960
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -135
  -137
  -155
  -179
  -211
  -252
  -304
  -369
  -447
  -540
  -646
  -772
  -915
  -1,076
  -1,254
  -1,449
  -1,662
  -1,892
  -2,139
  -2,402
  -2,681
  -2,975
  -3,285
  -3,610
  -3,949
  -4,304
  -4,673
  -5,058
  -5,458
  -5,874
Depreciation, amort., depletion, $m
  9
  13
  18
  25
  34
  46
  61
  80
  102
  128
  156
  190
  229
  273
  321
  373
  430
  491
  556
  625
  698
  775
  855
  940
  1,028
  1,120
  1,216
  1,316
  1,419
  1,527
Funds from operations, $m
  -126
  -124
  -137
  -154
  -177
  -206
  -243
  -289
  -345
  -412
  -491
  -582
  -686
  -803
  -933
  -1,076
  -1,233
  -1,402
  -1,583
  -1,777
  -1,983
  -2,201
  -2,430
  -2,670
  -2,921
  -3,184
  -3,458
  -3,743
  -4,039
  -4,347
Change in working capital, $m
  -13
  -20
  -27
  -37
  -49
  -64
  -80
  -98
  -118
  -139
  -162
  -185
  -209
  -232
  -256
  -280
  -303
  -325
  -347
  -369
  -390
  -411
  -431
  -451
  -471
  -491
  -512
  -532
  -553
  -575
Cash from operations, $m
  -112
  -104
  -109
  -117
  -127
  -142
  -163
  -191
  -227
  -273
  -329
  -397
  -477
  -571
  -677
  -797
  -930
  -1,077
  -1,236
  -1,409
  -1,593
  -1,790
  -1,999
  -2,219
  -2,450
  -2,693
  -2,946
  -3,210
  -3,486
  -3,772
Maintenance CAPEX, $m
  -4
  -7
  -10
  -16
  -23
  -32
  -44
  -59
  -77
  -99
  -125
  -156
  -190
  -229
  -273
  -321
  -373
  -430
  -491
  -556
  -625
  -698
  -775
  -855
  -940
  -1,028
  -1,120
  -1,216
  -1,316
  -1,419
New CAPEX, $m
  -27
  -39
  -55
  -75
  -99
  -128
  -160
  -197
  -237
  -279
  -324
  -371
  -418
  -466
  -513
  -560
  -606
  -652
  -696
  -739
  -781
  -823
  -863
  -904
  -944
  -984
  -1,025
  -1,067
  -1,109
  -1,153
Cash from investing activities, $m
  -31
  -46
  -65
  -91
  -122
  -160
  -204
  -256
  -314
  -378
  -449
  -527
  -608
  -695
  -786
  -881
  -979
  -1,082
  -1,187
  -1,295
  -1,406
  -1,521
  -1,638
  -1,759
  -1,884
  -2,012
  -2,145
  -2,283
  -2,425
  -2,572
Free cash flow, $m
  -144
  -150
  -175
  -207
  -249
  -302
  -367
  -446
  -541
  -651
  -778
  -923
  -1,085
  -1,265
  -1,463
  -1,678
  -1,910
  -2,158
  -2,423
  -2,703
  -2,999
  -3,311
  -3,637
  -3,978
  -4,334
  -4,705
  -5,091
  -5,493
  -5,910
  -6,344
Issuance/(repayment) of debt, $m
  -29
  90
  126
  171
  226
  291
  366
  449
  540
  637
  740
  846
  954
  1,063
  1,171
  1,279
  1,384
  1,487
  1,588
  1,687
  1,783
  1,877
  1,971
  2,063
  2,154
  2,247
  2,340
  2,434
  2,531
  2,631
Issuance/(repurchase) of shares, $m
  233
  147
  169
  198
  236
  285
  345
  419
  507
  611
  729
  866
  1,021
  1,194
  1,384
  1,592
  1,816
  2,058
  2,316
  2,590
  2,879
  3,184
  3,504
  3,839
  4,189
  4,554
  4,933
  5,329
  5,739
  6,166
Cash from financing (excl. dividends), $m  
  204
  237
  295
  369
  462
  576
  711
  868
  1,047
  1,248
  1,469
  1,712
  1,975
  2,257
  2,555
  2,871
  3,200
  3,545
  3,904
  4,277
  4,662
  5,061
  5,475
  5,902
  6,343
  6,801
  7,273
  7,763
  8,270
  8,797
Total cash flow (excl. dividends), $m
  60
  86
  120
  162
  214
  274
  344
  421
  506
  597
  690
  789
  889
  991
  1,092
  1,192
  1,291
  1,387
  1,481
  1,573
  1,663
  1,751
  1,838
  1,924
  2,009
  2,095
  2,182
  2,270
  2,360
  2,453
Retained Cash Flow (-), $m
  -233
  -147
  -169
  -198
  -236
  -285
  -345
  -419
  -507
  -611
  -729
  -866
  -1,021
  -1,194
  -1,384
  -1,592
  -1,816
  -2,058
  -2,316
  -2,590
  -2,879
  -3,184
  -3,504
  -3,839
  -4,189
  -4,554
  -4,933
  -5,329
  -5,739
  -6,166
Prev. year cash balance distribution, $m
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -169
  -61
  -49
  -36
  -23
  -10
  -1
  3
  -1
  -14
  -39
  -77
  -132
  -203
  -292
  -399
  -526
  -671
  -834
  -1,017
  -1,216
  -1,433
  -1,666
  -1,915
  -2,180
  -2,459
  -2,752
  -3,059
  -3,379
  -3,713
Discount rate, %
  15.80
  16.59
  17.42
  18.29
  19.20
  20.17
  21.17
  22.23
  23.34
  24.51
  25.74
  27.02
  28.37
  29.79
  31.28
  32.85
  34.49
  36.21
  38.02
  39.93
  41.92
  44.02
  46.22
  48.53
  50.96
  53.50
  56.18
  58.99
  61.94
  65.03
PV of cash for distribution, $m
  -146
  -45
  -30
  -18
  -9
  -3
  0
  1
  0
  -2
  -3
  -4
  -5
  -5
  -5
  -4
  -3
  -3
  -2
  -1
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  50.0
  5.5
  0.8
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

FINANCIAL RATIOS  of  Agenus Inc. (AGEN)

Valuation Ratios
P/E Ratio -1.9
Price to Sales 10.8
Price to Book -6.3
Price to Tangible Book
Price to Cash Flow -3.1
Price to Free Cash Flow -2.7
Growth Rates
Sales Growth Rate -8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 225%
Cap. Spend. - 3 Yr. Gr. Rate 67%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity -335.9%
Total Debt to Equity -335.9%
Interest Coverage -126
Management Effectiveness
Return On Assets -63.2%
Ret/ On Assets - 3 Yr. Avg. -64.2%
Return On Total Capital -91.7%
Ret/ On T. Cap. - 3 Yr. Avg. -140.3%
Return On Equity -793.8%
Return On Equity - 3 Yr. Avg. -474.4%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 66.7%
EBITDA Margin -526.1%
EBITDA Margin - 3 Yr. Avg. -481.1%
Operating Margin -465.2%
Oper. Margin - 3 Yr. Avg. -467.8%
Pre-Tax Margin -552.2%
Pre-Tax Margin - 3 Yr. Avg. -508.1%
Net Profit Margin -552.2%
Net Profit Margin - 3 Yr. Avg. -501.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 1.8%
Payout Ratio 0%

AGEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AGEN stock intrinsic value calculation we used $43 million for the last fiscal year's total revenue generated by Agenus Inc.. The default revenue input number comes from 0001 income statement of Agenus Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AGEN stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 15.8%, whose default value for AGEN is calculated based on our internal credit rating of Agenus Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Agenus Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AGEN stock the variable cost ratio is equal to 114%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $104 million in the base year in the intrinsic value calculation for AGEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 12.8% for Agenus Inc..

Corporate tax rate of 27% is the nominal tax rate for Agenus Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AGEN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AGEN are equal to 104.6%.

Life of production assets of 10.7 years is the average useful life of capital assets used in Agenus Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AGEN is equal to -52.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-75.815792 million for Agenus Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 131.108 million for Agenus Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Agenus Inc. at the current share price and the inputted number of shares is $0.4 billion.

RELATED COMPANIES Price Int.Val. Rating
MRK Merck & Compan 82.29 44.01  sell
GSK GlaxoSmithKlin 41.25 65.66  str.buy
INCY Incyte Corpora 85.34 1.82  str.sell
STML Stemline Thera 12.37 0.28  str.sell
VICL Vical Incorpor 1.23 0.56  str.sell
CLDX Celldex Therap 4.94 1.52  str.sell

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.